Result
€114,059 ▲ 562%
The result rose in 2025 from €17,236 to €114,059.
EVO
Lifetime
2 annual accounts with figures on one time axispeak €164,404 (2025)
€164,404▲ 573%
peak €114,059 (2025)
€114,059▲ 562%
peak €132,295 (2025)
€132,295▲ 625%
€148,543▲ 229%
Board1 name since 2024
1 director
Documentsfilings and deeds
20-07-202611 days before the deadline
2025micro format
Gross margin from €24,425 to €164,404Result from €17,236 to €114,059Equity from €18,236 to €132,295Debts from €45,102 to €148,543Investments €88,842Cash from €3,784 to €17,138
Key points
from the 2025 annual accountsTurnover
≈ €310,000 estimated
The micro format states no turnover.
Debts
€148,543 ▲ 229%
Debts rose by €103,441 in 2025.
Investments
€88,842 5.8 × depreciation
Green is investment, beige is depreciation.
Liquidity
2.25 was 0.85 in 2024
Short-term debts rose from €35,102 to €77,427.
Starting capital
€1,000 1,000 shares
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 39,274 companies had the same profile as EVO has now. Each dot stands for 99 companies, two years later.
95.8%
were still trading
2.3%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,274 companies, not a prediction for EVO. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1013386021
Incorporation
Founding capital of €1,000, 1,000 shares · Founder: · Appointment: (director) · published on 12-09-2024 · Gazette deed
First establishment
Wetstraat 89, Antwerp
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| EVO Antwerp | €280,838 | €164,404 | 47.1% | - |
| LAU'RL Le Roeulx | €292,144 | €168,059 | 66.6% | - |
| JKPML Chaumont-Gistoux | €257,488 | €163,478 | 71.6% | - |
| MVH Emergency and Expedition Medicine Merelbeke-Melle | €251,932 | €166,606 | 66.4% | - |
| DR DEBORAH BUISSERET Lessines | €263,377 | €169,642 | 40.9% | - |
| LECOMTE ORL Care Gouvy | €296,468 | €154,496 | 40.0% | - |
| DOKTER VINCENT ALBERTS Hasselt | €242,819 | €165,488 | 64.3% | - |
These companies have the same main activity as EVO: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €243,000 and €296,000, founded between 2024 and 2025.
Official details
Source: KBO- Status
- Active since 10-09-2024Normal situation
- Activity
- Specialist medical practiceNACE 86220and 2 others
- Establishment unit
- 2.363.701.5422060 Antwerp, since 10-09-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 27-08-2025
Annual accounts 2025
- €280,838▲ 343%
- Filing
- Filed on 20-07-2026, 11 days before the end of the filing period
Insights on EVO
EVO has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €132,295 and a net result of €114,059.
Its solvency ranks better than 37% of 21,311 sector peers (NACE 86, financial year 2025).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about EVO
- What is the company number of EVO?
- The company number of EVO is 1013.386.021. The VAT number is the same number with BE in front: BE 1013.386.021.
- Where is EVO based?
- The registered office is at Wetstraat 89, 2060 Antwerp.Company details
- What does EVO do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of EVO?
- EVO is a private limited company (BV).
- When was EVO founded?
- EVO was founded on 10-09-2024.
- Is EVO still active?
- Yes, EVO is an active enterprise in the KBO register.
- What is the turnover of EVO?
- The turnover in financial year 2025 is ≈ €310,000. This figure is estimated from the gross margin of €164,404 and 41 comparable companies (NACE 86220). It probably lies between €260,000 and €410,000.Financials
- Is EVO profitable?
- In financial year 2025, EVO made a profit of €114,059.
- Where can I find the annual accounts of EVO?
- EVO filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of EVO due?
- EVO must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.